Putnam Investments LLC Biocryst Pharmaceuticals Inc Transaction History

Putnam Investments LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $21,944 - $27,777	3,153 Added 7.99%	42,632 $300,000
Q1 2023 May 22, 2023	SELL	$7.94 - $11.84 $13,132 - $19,583	-1,654 Reduced 4.02%	39,479 $329,000
Q4 2022 Feb 14, 2023	SELL	$10.5 - $14.2 $231 - $312	-22 Reduced 0.05%	41,133 $472,000
Q3 2022 Nov 14, 2022	SELL	$10.79 - $14.81 $8,070 - $11,077	-748 Reduced 1.79%	41,155 $518,000
Q2 2022 Aug 15, 2022	SELL	$7.89 - $17.88 $4,087 - $9,261	-518 Reduced 1.22%	41,903 $443,000
Q1 2022 May 16, 2022	SELL	$11.56 - $19.76 $34,969 - $59,774	-3,025 Reduced 6.66%	42,421 $690,000
Q4 2021 Feb 14, 2022	BUY	$11.18 - $15.46 $508,086 - $702,595	45,446 New	45,446 $629,000

280

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Putnam Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Putnam Investments LLC with notifications on news.